Jan Malcolm Sells 50 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 50 shares of the firm’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $460.98, for a total transaction of $23,049.00. Following the transaction, the director directly owned 320 shares of the company’s stock, valued at $147,513.60. The trade was a 13.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Jan Malcolm also recently made the following trade(s):

• On Monday, January 5th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $495.01, for a total value of $24,750.50.
• On Tuesday, December 23rd, Jan Malcolm sold 50 shares of United Therapeutics stock. The shares were sold at an average price of $512.12, for a total value of $25,606.00.
• On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $482.98, for a total value of $24,149.00.

United Therapeutics Stock Performance

United Therapeutics stock opened at $469.77 on Thursday. The firm has a market cap of $20.23 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 2.51 and a beta of 0.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $519.99. The firm has a 50 day moving average price of $487.41 and a two-hundred day moving average price of $412.47.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $6.39 earnings per share. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. Morgan Stanley set a $447.00 price objective on United Therapeutics in a research note on Wednesday, October 29th. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. HC Wainwright increased their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $509.50.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently modified their holdings of the stock. Geneos Wealth Management Inc. lifted its position in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in United Therapeutics by 77.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after purchasing an additional 2,655 shares during the period. IFM Investors Pty Ltd increased its stake in shares of United Therapeutics by 6.6% in the second quarter. IFM Investors Pty Ltd now owns 8,519 shares of the biotechnology company’s stock worth $2,448,000 after purchasing an additional 529 shares in the last quarter. Diversified Trust Co increased its stake in shares of United Therapeutics by 73.1% in the second quarter. Diversified Trust Co now owns 3,188 shares of the biotechnology company’s stock worth $916,000 after purchasing an additional 1,346 shares in the last quarter. Finally, Sowell Financial Services LLC bought a new stake in shares of United Therapeutics in the second quarter valued at approximately $333,000. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.